Appili to present update on topical formulation of paromomycin ATI-1801 already shown to be safe and effective against the disfiguring disease, cutaneous leishmaniasis, in Phase 3 study
HALIFAX, Nova Scotia, August 2, 2022– Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Armand Balboni, M.D, Ph.D, Chief Executive Officer, and Yoav Golan, M.D, Chief Medical Officer of Appili, will participate at the seventh iteration of WorldLeish, from August 1 to 6 2022, and present an update on Appili program ATI-1801.
The presentation will include an overview of, Appili’s new late-stage program ATI-1801to treat cutaneous leishmaniasis (“CL”), the most common form of leishmania that affects hundreds of thousands of people around the world annually and is characterized by the formation of lesions and ulcers that often lead to scarring, disfigurement, and stigmatization for those infected. CL is a serious impediment to socioeconomic development, especially for women, and a priority for public health authorities and non-governmental organizations around the world.
Presentation details for Appili are as follows:
Date: August 4th , 2022
Time: 10AM COT / 11AM ET
Location: Programa de Estudio y Control de Enfermedades Tropicales of the Universidad de Antioquia, Colombia
Appili management will also be conducting in-person meetings throughout the conference. To request a meeting, please register for the conference here.
About ATI-1801
Licensed from the U.S. Department of Defense through the U.S. Army Medical Materiel Development Activity, Appili’s ATI-1801 is a novel topical product with demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies. As current treatments are often invasive and require hospitalization, ATI-1801 has the potential to significantly reduce suffering from CL by providing patients in need with a safe and effective topical therapy that can be used in the outpatient setting.
“ATI-1801 is a unique opportunity to build on an extensive data set and bring an urgently needed treatment to patients around the world” said Dr. Armand Balboni, M.D., Ph.D., Chief Executive Officer of Appili Therapeutics. “Appili is proud to play a part in developing a solution to this long-neglected disease, and Dr. Golan and I are greatly looking forward to sharing our progress at WorldLeish7.”
About WorldLeish
WorldLeish is the world’s most important academic and scientific event on leishmaniasis, a disfiguring skin infection that affects hundreds of thousands of people around the world annually.
In its seventh version, WorldLeish expects the participation of 1,000 researchers, health professionals, and authorities and from all over the world who will meet to discuss and share the latest advances in research and successful experiences around neglected tropical diseases. As well as strengthening alliances between companies, governments, research and technology centers around a common interest: to be able to control, prevent and find new treatment alternatives for leishmaniasis as a global public health problem.
About Appili Therapeutics
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including a broad-spectrum antifungal, a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic product for the treatment of a disfiguring disease, and two novel antibiotic programs. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.
Forward Looking Statements
This news release contains “forward-looking statements”, including with respect the potential for ATI-1801 as a treatment for CL. Wherever possible, words such as “may,” “would,” “could,” “should,” “will,” “anticipate,” “believe,” “plan,” “expect,” “intend,” “estimate,” “potential for” and similar expressions have been used to identify these forward-looking statements. These forward-looking statements reflect the current expectations of the Company’s management for future growth, results of operations, performance and business prospects and opportunities and involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, those listed in the annual information form of the Company dated June 23, 2022, and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.
###
Media Contact:
Danielle Raabe/APCO Worldwide
T: 1-646-717-9915
E: DRaabe@apcoworldwide.com
Investor Relations Contact:
Armand Balboni, CEO
Appili Therapeutics
E: Info@AppiliTherapeutics.com
